Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy

Radiology. 1996 Feb;198(2):327-32. doi: 10.1148/radiology.198.2.8596826.

Abstract

Purpose: To determine the mammographic features of locally advanced breast carcinoma treated with neoadjuvant chemotherapy and to evaluate the accuracy of mammography in the prediction of residual carcinoma.

Materials and methods: Of 90 women treated with hormonally synchronized cytotoxic therapy before mastectomy or lumpectomy for advanced breast carcinoma, 56 were selected because they had undergone mammography before and after neo-adjuvant therapy. Mammographic and clinical opinion on the presence of residual disease was compared with histologic results.

Results: Fifty-four (96%) of 56 women had a complete (n = 34 [61%]) or partial (n = 20 [36%]) clinical response. Thirteen (23%) of 56 women had no residual tumor. Sensitivity of mammography in the prediction of residual carcinoma was greater than that of clinical examination (79% vs 49%), but specificity was lower (77% vs 92%). In 24 women with inflammatory carcinoma, sensitivity of mammography was 78% while that of clinical examination was 39%; specificity was equal (83%).

Conclusion: Mammography was more sensitive than clinical examination in the prediction of residual carcinoma; it was not accurate enough to obviate surgical biopsy.

Publication types

  • Comparative Study

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / diagnosis
  • Breast Neoplasms / diagnostic imaging*
  • Breast Neoplasms / drug therapy*
  • Carcinoma, Ductal, Breast / diagnosis
  • Carcinoma, Ductal, Breast / diagnostic imaging*
  • Carcinoma, Ductal, Breast / drug therapy*
  • Carcinoma, Lobular / diagnosis
  • Carcinoma, Lobular / diagnostic imaging*
  • Carcinoma, Lobular / drug therapy*
  • Chemotherapy, Adjuvant
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Estrogens, Conjugated (USP) / administration & dosage
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Mammography
  • Methotrexate / administration & dosage
  • Middle Aged
  • Neoplasm, Residual
  • Predictive Value of Tests
  • Retrospective Studies
  • Sensitivity and Specificity
  • Tamoxifen / administration & dosage

Substances

  • Antineoplastic Agents
  • Estrogens, Conjugated (USP)
  • Tamoxifen
  • Doxorubicin
  • Cyclophosphamide
  • Fluorouracil
  • Methotrexate